Changing the tone of clinical study design in the cannabis industry
Cannabis (also known as marijuana) is the most frequently used psychoactive substance globally. Cannabis exerts therapeutic functions for many indications and has vast potential as a health and wellness product. Advances in our understanding of the composition and pharmacological properties of canna...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2020-02-01
|
| Series: | Translational Neuroscience |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/tnsci-2020-0002 |
| _version_ | 1797987817498869760 |
|---|---|
| author | Antony Joseph M McDonald Alison C. Noorbakhsh Farshid Guthrie Najla Evans Mal |
| author_facet | Antony Joseph M McDonald Alison C. Noorbakhsh Farshid Guthrie Najla Evans Mal |
| author_sort | Antony Joseph M |
| collection | DOAJ |
| description | Cannabis (also known as marijuana) is the most frequently used psychoactive substance globally. Cannabis exerts therapeutic functions for many indications and has vast potential as a health and wellness product. Advances in our understanding of the composition and pharmacological properties of cannabis have revealed interactions between cannabis, an individuals’ circadian rhythms and their endocannabinoid signaling. Exogenously administered cannabinoids can bidirectionally entrain central and peripheral clocks that comprise circadian rhythms, and malfunctions in the endocannabinoid system are reported to impact neurological processes. Therefore, it is necessary to account for the circadian rhythm when designing clinical trials examining the pharmacological properties of cannabis-based products for health and wellness to limit its potential confounding impact on results. Consideration of the entrainment capabilities of the endocannabinoid system is warranted when designing clinical trials. |
| first_indexed | 2024-04-11T07:53:14Z |
| format | Article |
| id | doaj.art-dd78670b35a3418d8e0f71dbe33e48be |
| institution | Directory Open Access Journal |
| issn | 2081-6936 |
| language | English |
| last_indexed | 2024-04-11T07:53:14Z |
| publishDate | 2020-02-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Translational Neuroscience |
| spelling | doaj.art-dd78670b35a3418d8e0f71dbe33e48be2022-12-22T04:36:01ZengDe GruyterTranslational Neuroscience2081-69362020-02-011114910.1515/tnsci-2020-0002tnsci-2020-0002Changing the tone of clinical study design in the cannabis industryAntony Joseph M0McDonald Alison C.1Noorbakhsh Farshid2Guthrie Najla3Evans Mal4KGK Science London, LondonCanadaKGK Science London, LondonCanadaDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranKGK Science London, LondonCanadaKGK Science London, LondonCanadaCannabis (also known as marijuana) is the most frequently used psychoactive substance globally. Cannabis exerts therapeutic functions for many indications and has vast potential as a health and wellness product. Advances in our understanding of the composition and pharmacological properties of cannabis have revealed interactions between cannabis, an individuals’ circadian rhythms and their endocannabinoid signaling. Exogenously administered cannabinoids can bidirectionally entrain central and peripheral clocks that comprise circadian rhythms, and malfunctions in the endocannabinoid system are reported to impact neurological processes. Therefore, it is necessary to account for the circadian rhythm when designing clinical trials examining the pharmacological properties of cannabis-based products for health and wellness to limit its potential confounding impact on results. Consideration of the entrainment capabilities of the endocannabinoid system is warranted when designing clinical trials.https://doi.org/10.1515/tnsci-2020-0002cannabinoidbrain activitycircadian rhythmsclinical trials |
| spellingShingle | Antony Joseph M McDonald Alison C. Noorbakhsh Farshid Guthrie Najla Evans Mal Changing the tone of clinical study design in the cannabis industry Translational Neuroscience cannabinoid brain activity circadian rhythms clinical trials |
| title | Changing the tone of clinical study design in the cannabis industry |
| title_full | Changing the tone of clinical study design in the cannabis industry |
| title_fullStr | Changing the tone of clinical study design in the cannabis industry |
| title_full_unstemmed | Changing the tone of clinical study design in the cannabis industry |
| title_short | Changing the tone of clinical study design in the cannabis industry |
| title_sort | changing the tone of clinical study design in the cannabis industry |
| topic | cannabinoid brain activity circadian rhythms clinical trials |
| url | https://doi.org/10.1515/tnsci-2020-0002 |
| work_keys_str_mv | AT antonyjosephm changingthetoneofclinicalstudydesigninthecannabisindustry AT mcdonaldalisonc changingthetoneofclinicalstudydesigninthecannabisindustry AT noorbakhshfarshid changingthetoneofclinicalstudydesigninthecannabisindustry AT guthrienajla changingthetoneofclinicalstudydesigninthecannabisindustry AT evansmal changingthetoneofclinicalstudydesigninthecannabisindustry |